Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID.
Fiche publication
Date publication
octobre 2023
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Uzzan M, Nachury M, Nuzzo A, Amiot A, Caron B, Benezech A, Buisson A, Bouguen G, Le Berre C, Reenaers C, Le Cosquer G, Savoye G, Charkaoui M, Vidon M, Guillo L, Fumery M, Peyrin-Biroulet L, Kirchgesner J, Bouhnik Y,
Lien Pubmed
Résumé
While ulcerative proctitis (UP) can dramatically impair quality-of-life, treatments efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomized controlled trials in ulcerative colitis.
Mots clés
Ulcerative proctitis, refractory proctitis, tofacitinib
Référence
J Crohns Colitis. 2023 10 5;: